null - FindTrial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224958

Enrollment

150

Registered

2019-11-21

Start date

2019-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : Concizumab Therapeutic category code : 634 Human blood preparations Dosage and Administration for Investigational mate

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
safety	—

Countries

Europe, Japan, North America

Outcome results